Results 1 to 10 of about 24,510 (117)

Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections. [PDF]

J Med Virol
ABSTRACT This study aimed to assess the humoral immune response following administration of a BNT162b2 mRNA COVID‐19 booster dose and to evaluate its association with the development of SARS‐CoV‐2 infection after vaccination. Between July 2021 and February 2022, serum samples were collected from 313 individuals 28 days after receiving a COVID‐19 ...
Dinç HÖ, Uysal HK, Can G, Budak B, Daşdemir FO, Keskin E, Aydoğan O, Balkan İİ, Karaali R, Saribaş S, Ergin S, Saltoğlu N, Kocazeybek B.   +12 more
europepmc   +2 more sources

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results) [PDF]

Vaccines
Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability ...
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, Rohit Solan, Han Wu, Hua Ma, Xia Xu, Federico J. Mensa, Todd Belanger, David Cooper, Robin Mogg, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Pirada Suphaphiphat Allen, Kayvon Modjarrad, Alejandra Gurtman, Kelly Lindert   +17 more
doaj   +2 more sources

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2023
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant ...
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šusteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Human Vaccines & Immunotherapeutics, 2023
Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable ...
Moe H. Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava   +4 more
doaj   +1 more source

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Vaccines, 2023
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in ...
Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, Bruce T. Liang   +10 more
doaj   +1 more source

Granulomatous anterior uveitis following mRNA-based COVID-19 vaccination: A case report

Indian Journal of Ophthalmology, 2023
A 23-year-old patient presented with complaints of redness, pain, photophobia, and blurred vision in the right eye 15 days after she received the third dose of BNT162b2 vaccination.
Furkan Cam, Gizem Gok, Hande Celiker
doaj   +1 more source

To vaccinate or not to vaccinate – BNT162b2 seroconversion rate and side effects among Polish healthcare workers

International Journal of Occupational Medicine and Environmental Health, 2022
Objectives The study aimed to analyze the effect of BNT162b2 vaccination among Polish healthcare workers in terms of serologic response and adverse events.
Bartosz Siewert, Anna Szabat, Małgorzata Chądzińska-Cebula, Natalia Purpurowicz-Miękus, Piotr Sujkowski, Rafał Spachacz, Grzegorz Dworacki, Jacek Wysocki, Danuta Januszkiewicz-Lewandowska, Ewelina Gowin   +9 more
doaj   +1 more source

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases

Human Vaccines & Immunotherapeutics, 2023
The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two widely used COVID-19 vaccines that confer immune protection to healthy individuals. However, hesitancy toward COVID-19 vaccination appeared to be common for patients with neuromuscular
Michael Kwan Leung Yu, Sophelia Hoi Shan Chan, Samuel Cheng, Daniel Leung, Sau Man Chan, Amy Suen Ka Yan, Wilfred Hing Sang Wong, Malik Peiris, Yu Lung Lau, Jaime S Rosa Duque   +9 more
doaj   +1 more source

COVID-19 vaccine in the Kingdom of Saudi Arabia: A true operation warp speed

Journal of Nature and Science of Medicine, 2021
As of January 2021, 1 year has passed since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first discovered, which is the cause of the coronavirus disease-2019 (COVID-19) pandemic that has infected almost 100 million people ...
Mazin Barry, Ahmed S BaHammam
doaj   +1 more source

Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?

Journal of Pharmaceutical Policy and Practice, 2022
The Joint Committee on Vaccination and Immunisation (JCVI) in UK has recently advised that COVID vaccines in 5–11-year-old children is non-essential. This has created an outrage among some healthcare professionals who believed a mandatory vaccination ...
Hamid A. Merchant
doaj   +1 more source